TREACE MEDICAL CONCEPTS, INC. (TMCI) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR TREACE MEDICAL CONCEPTS, INC. (TMCI) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
TREACE MEDICAL CONCEPTS, INC. Q3 2025 10-Q Analysis
Risk Factors
- • Newly added litigation risk triggered by October 2024 and May/August 2025 lawsuits against Stryker and Zimmer Biomet for patent infringement seeking damages and injunctive relief
- • Most materially updated financial risk: inclusion of $11.0 million initial stocking distributor sales in 9M 2025, expected not to recur, impacting revenue recognition
TREACE MEDICAL CONCEPTS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$50M
▲ +11.4% YoY▲ +6.0% QoQ
Net Income
-$16M
▼ -6.0% YoY▲ +6.4% QoQ
Gross Margin
79.1%
▼ -107bp YoY▼ -59bp QoQ
Operating Margin
-31.2%
▲ +235bp YoY▲ +460bp QoQ
Net Margin
-32.4%
▲ +163bp YoY▲ +428bp QoQ
ROE
-18.3%
Total Assets
$197M
EPS (Diluted)
$-0.26
▼ -4.0% YoY▲ +7.1% QoQ
Operating Cash Flow
-$9M
▲ +23.2% YoY▼ -198.1% QoQ
Source: XBRL data from TREACE MEDICAL CONCEPTS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on TREACE MEDICAL CONCEPTS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.